Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
Holladay
M W
MW
Abbott Laboratories, Illinois 60064-3500, USA. mark.w.holladay@abbott.com
Dart
M J
MJ
Lynch
J K
JK
D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D001665:Binding Sites; D004298:Dopamine / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D015394:Molecular Structure; D009420:Nervous System / Q000187:drug effects / Q000378:metabolism*; D009474:Neurons / Q000737:chemistry*; D009538:Nicotine / Q000378:metabolism / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000737:chemistry / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000737:chemistry / Q000494:pharmacology*; D011978:Receptors, Nicotinic / Q000737:chemistry / Q000145:classification / Q000378:metabolism*; D013329:Structure-Activity Relationship
D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D011978:Receptors, Nicotinic; D009538:Nicotine; D000109:Acetylcholine; D004298:Dopamine